Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Aug 07 | Strand Therapeutics Secures $153M in Series B Funding to Advance Programmable mRNA Pipeline read more »
Aug 05 | Purespring Therapeutics Receives UK Approval for PS-002 AAV Gene Therapy Trial in IgA Nephropathy read more »
Aug 05 | HHS Ends mRNA Vaccine Development Funding read more »
News:
Aug 06 | Iovance Restructures Operations Following Financial Guidance Revision read more »
Aug 05 | Lineage Cell Therapeutics Doses First Chronic SCI Patient in Landmark DOSED Study for Allogeneic Cell Therapy read more »
Aug 01 | Hansa Biopharma Announces Positive Data for Enabling Duchenne Muscular Dystrophy Gene Therapy read more »
Aug 01 | PolTREG and Immuthera Advance TREG Cell Therapy for Type 1 Diabetes with Positive FDA Feedback read more »
Jul 31 | Be Biopharma Begins Cell Therapy Trial for Hemophilia B read more »
Jul 31 | 4D Molecular Therapeutics Announces Positive AAV Gene Therapy Data for Diabetic Macular Edema read more »
Jul 31 | Moderna’s mRNA Strategy Shifts as Q2 Losses Deepen read more »
Jul 30 | XellSmart Doses World’s First Patient in Spinal Cord Injury Cell Therapy Trial read more »
Articles:
Aug 05 | Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function read more »
Aug 05 | The hidden risks of CRISPR/Cas: structural variations and genome integrity read more »
Aug 05 | PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation read more »
Aug 04 | A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles read more »
Aug 04 | Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles read more »
Aug 04 | Preclinical safety and biodistribution of SPVN06, a novel gene- and mutation-independent gene therapy for rod-cone dystrophies read more »
Aug 02 | Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer read more »
Aug 01 | Discrete Immolative Guanidinium Transporters deliver mRNA to specific organs and red blood cells read more »
Jul 31 | GFP-on mouse model for interrogation of in vivo gene editing read more »
Jul 28 | Safety of JN.1-Updated mRNA COVID-19 Vaccines read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
